Trajectories of Nonmedical Prescription Drug Misuse

非医疗处方药滥用的轨迹

基本信息

批准号：
9908065
负责人：
SEAN ESTEBAN MCCABE
金额：
$ 35.88万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-06-01 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9908065
关键词：
17 year old Address Adolescence Adolescent Adolescent and Young Adult Adult Age Combined Modality Therapy Data Development Disease Drug abuse Employment Equation Exposure to Future Growth Health Health Professional Individual Investigation Knowledge Life Longitudinal Studies Measures Medical Modality Modeling Monitor Parents Pattern Pharmaceutical Preparations Prescription opioid overdose Prevention Research Research Design Risk Risk Factors Sample Size Sampling Schedule Structure Substance Use Disorder Symptoms Techniques Time Tranquilizing Agents United States National Institutes of Health Weight Work adverse outcome base clinical practice cohort functional outcomes misuse of prescription only drugs nonmedical use prescription drug abuse prescription opioid prescription opioid misuse protective factors rate of change response secondary analysis sedative theories twelfth grade young adult

项目摘要

PROJECT SUMMARY/ABSTRACT In response to PAR-18-062: Accelerating the Pace of Drug Abuse Research Using Existing Data, this competing renewal “Trajectories of Nonmedical Prescription Drug Misuse” builds on our parent R01 and proposes to use national data to assess the longitudinal relationships among trajectories of medical and nonmedical use of prescription medications, functional outcomes and adverse consequences from adolescence (age 18) to middle adulthood (age 50). The proposed research will focus on prescription opioids, sedatives/tranquilizers, and stimulants because the medical and nonmedical use of these medications and related consequences have increased over the past three decades in the U.S. To date, no national studies have examined the impact of attrition on medical and nonmedical use estimates in longitudinal studies. Moreover, national studies fail to examine long-term functional outcomes or adverse outcomes associated with different trajectories of medical and nonmedical use of prescription medications. More longitudinal studies of adolescents followed into middle adulthood are needed because adults are more likely to be prescribed scheduled medications and often assume greater life/work responsibilities. As a result, we propose secondary analyses focusing primarily on the MTF longitudinal panel sample, which features 11 separate cohorts of approximately 26,400 high school seniors (modal age 18) who were followed 1-2 years (ages 19-20), 3-4 years (ages 21-22), 5-6 years (ages 23-24), 7-8 years (ages 25-26), 9-10 years (ages 27-28), 11-12 years (ages 29- 30), 17 years (age 35), 22 years (age 40), 27 years (age 45), and 32 years later (age 50) resulting in 11 overall waves of data. The MTF data provide a unique opportunity with sufficient measures and sample sizes for examining relationships over 32 years and to meet the objectives of our study, which aims to: 1) estimate the bias in estimated rates of medical and nonmedical use of prescription opioids, sedatives/tranquilizers, and stimulants at different developmental periods and in estimated rates of change over time in medical and nonmedical use due to differential attrition, by comparing and evaluating alternative weighting and imputation approaches; 2) identify the trajectories of medical and nonmedical use of prescription opioids, sedatives/tranquilizers, and stimulants based on multiple waves of longitudinal data from adolescence (age 18) to middle adulthood (age 50); 3) use growth mixture modeling to evaluate whether subject-specific trajectories of nonmedical and medical use of prescription opioids, sedatives/tranquilizers, and stimulants from adolescence to age 45 are predictive of functional outcomes (e.g., educational attainment) and adverse consequences (e.g., SUD symptoms) at age 50; and 4) examine the adolescent risk and protective factors for trajectories of medical and nonmedical use of prescription medications that are associated with poor functional outcomes and adverse consequences in middle adulthood using a theory-based developmental model.

项目摘要/摘要为了回应PAR-18-062：使用现有数据加速滥用药物滥用研究的速度，这竞争的续签“非医学处方药滥用轨迹”建立在我们的父母R01上，并且建议使用国家数据来评估医学轨迹之间的纵向关系非医学使用处方药，功能结果和不利后果青少年（18岁）至成年中期（50岁）。拟议的研究将侧重于处方阿片类药物，镇静剂/镇静剂以及兴奋剂，因为这些药物的医学和非医学使用以及迄今为止，在美国过去的三十年中，相关后果有所增加，没有国家研究在纵向研究中检查了属性对医学和非医学使用估计的影响。此外，国家研究未能检查与相关的长期功能结果或不利结果处方药的医学和非医学使用轨迹的不同轨迹。更多的纵向研究需要进入成年中期的青少年，因为成年人更有可能被处方预定药物，通常承担更大的生活/工作责任。结果，我们提出了次要分析主要关注MTF纵向面板样本，该样本具有11个单独的同类群体大约有26,400名高中生（18岁年龄段），他们受到1-2岁（19-20岁），3 - 4年（21-22岁），5-6岁（23-24岁），7-8岁（25-26岁），9-10岁（27-28岁），11-12岁（29-年龄 30），17岁（35岁），22岁（年龄40岁），27岁（45岁）和32年后（50岁），总体11 数据波。 MTF数据提供了一个独特的机会，并提供了足够的措施和样本量检查32年以上的关系并达到我们研究的目标，该目标的目的是：1）估计处方阿片类药物，镇静剂/镇静剂的医学和非医学使用率偏见在不同的发育时期和医疗时间随时间变化的估计变化率和估计的兴奋剂通过比较和评估替代加权和插补，由于差异属性而导致的非医学用途方法； 2）确定处方阿片类药物的医学和非医学使用轨迹，镇静剂/镇静剂和基于青少年纵向数据的多波（18岁）的刺激物到成年中期（50岁）； 3）使用生长混合物建模来评估主体特定的轨迹处方阿片类药物，镇静剂/镇静剂的非医学和医疗用途以及来自青少年至45岁的青少年可以预测功能结果（例如，教育程度）和不利 50岁时的后果（例如SUD符号）； 4）检查青少年风险和受保护因素与功能不良有关的处方药的医学和非医学使用轨迹使用基于理论的发展模型在成年中期的结果和不利后果。